Mild disease | Moderate disease (no respiratory compromise)* | Severe disease (respiratory compromise present) | Comment | |
Immunocompetent hosts |
| |||
No risk factors for complications | No treatment. | Initiate therapy with fluconazole (400 mg orally daily) or itraconazole (200 mg orally twice daily). Duration is typically 6 to 12 weeks.Δ | Initiate therapy with amphotericin B and a triazole antifungal, such as fluconazole (400 to 800 mg orally daily) or itraconazole (200 mg orally twice daily). Transition to triazole monotherapy when clinically stable. Duration is typically 12 to 24 weeks.Δ | |
Risk factors for complications:
| Decision to treat is made on a case-by-case basis.¶ If treatment is initiated, administer fluconazole (400 mg orally daily) or itraconazole (200 mg orally twice daily). Duration is typically 6 to 12 weeks.Δ | |||
Immunocompromised hosts | ||||
Immunocompromised hosts that are at high risk for severe disease:
| Initiate therapy with fluconazole (400 mg orally daily) or itraconazole (200 mg orally twice daily). Duration depends upon underlying condition. In addition, some patients may require suppressive therapy.§ | Initiate therapy with fluconazole (400 mg orally daily) or itraconazole (200 mg orally twice daily). Duration depends upon underlying condition. In addition, some patients may require suppressive therapy.§ | Initiate therapy with amphotericin B and a triazole antifungal, such as fluconazole (400 to 800 mg IV or orally daily) or itraconazole (200 mg orally twice daily). Transition to triazole monotherapy when clinically stable. Duration depends upon underlying condition. In addition, some patients may require suppressive therapy.§ |
TNF: tumor necrosis factor; CAR: chimeric antigen receptor; IFN: interferon; IV: intravenous.
* Commonly used indicators for moderate disease include: infiltrates involving more than half of one lung or portions of both lungs, regardless of symptoms; persistent symptoms, including night sweats, for longer than three weeks; greater than 10% loss of body weight; anticoccidioidal complement-fixing antibody concentrations ≥1:32.
¶ These patients may be at risk for pulmonary or extrapulmonary complications. The decision to treat must balance the potential risks and benefits of treatment with azole therapy versus continued monitoring. Refer to the UpToDate topic on primary pulmonary coccidioidomycosis for a more detailed discussion.
Δ Duration depends in part upon the patient's response to therapy. Refer to the UpToDate topic that discusses primary pulmonary coccidioidomycosis for a discussion of duration of treatment.
◊ Refer to the UpToDate topics that discuss treatment of primary pulmonary coccidioidomycosis and coccidioidomycosis in immunocompromised hosts for discussions of monitoring.
§ Refer to the UpToDate topic that discusses coccidioidomycosis in immunocompromised hosts for a discussion of duration of treatments and the need for suppressive therapy in individual patient groups.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟